we caught up with the cofounder and ceo of regeneron. happy anniversary for regeneron.stry and third longest-serving ceo in the s&p. >> it's been a long time. it's been incredibly exciting. i think the future is even more exciting. >> you are our first guest on mad money and the stock was at 5. >> it is now 800 and 900. when i came on the show nobody would talk about it and nobody was interested. you put us on the map and helped us get through the lien time. i really appreciate it. >> of course. it was you and your genius scientists. >> we have been doing it together since we started the company. it has been an incredible run but we just can't wait to keep going. >> now this turned out to be an amazing drug. some analysts were upset yesterday that you mr. numbers, but this is a gigantic franchise. >> absolutely. it's one of the most important franchises treat people with age-related macular degeneration or diabetic eye disease. it was about $123 million in the fourth quarter. it is a fabulous launch. >> we don't talk enough about a wonder drug that you have that can be

sort through and you will find gems out there regeneron has been fantastic. >> we also own regeneron,and eli lilly. one point on biotechs overall, rates rise, it's a challenging environment for them >>> coming up, we will trade more stocks on the move. two big winners, two big loss.er first, mike santoli, his "midday word" is next. at pgim, finding opportunity in fixed income today, helps secure tomorrow. our time-tested fixed income suite, backed by over 145 years of risk experience, helps investors meet their goals. pgim investments. shaping tomorrow today. you can't buy great conversations or moments that matter, but you can invest in them. at t. rowe price our strategic investing approach can help you build the future you imagine. t. rowe price, invest with confidence. (ella) fashion moves fast. can help you build setting trends is our business. we need to scale with customer demand... in real time. (jen) so we partner with verizon. their solution for us? a private 5g network. (ella) we now get more control of production, efficiencies, and greater agility. (marquis) with a custom

again, degas wright's picks are microsoft and regeneron and klc.have to wait to see if tech continues leadership today. we have seen a rise in rates. how would you play tech where we see higher valuations and rates moving higher? >> we look at that a.i. theme and you want to focus on the megaruptors and supplies to the industry and those that can do applications. you have to look under the hood and understand. >> does it make you feel bullish or concerned it will pull back? >> we are still bullish risk-on in this market because we feel that the aspects of the market are artificial intelligence. you talked about cybersecurity earlier. those will be drivers into 2024. >> degas, we have to leave it there. ghe dow would open up 50 points hier. that is it for us. "squawk box" is coming up next. (♪♪) (♪♪) (♪♪) were you worried the wedding would be too much? nahhhh... [inner monologue] another destination wedding?! we just got back from her sister's in napa. who gets married in napa? my daughter. who gets married someplace more expensive? my other daughte

if it is weak, i'm going to continue to buy it. >> regeneron is also before the bell friday.get some guidance in terms of the top and bottom lines, but this is a biotech that i believe is a core holding, large-cap biotech, one of my favorite names. >> abvie, jason? >> the news with humira last year was a little of a pullback on the stock, but the pipeline is relatively strong, and the price action has been solid over the last three months. 16% and 6% year-to-date. >> we are going to bounce for a couple and come back and do "final trades." dow still hanging on to positive territory. ♪♪ sofi is helping me get my money right to achieve my ambitions. wanna see? ♪♪ ♪♪ like earning more money on my money as a head chef. ready for service? yes, chef! and saving. to give back to local producers. sofi can help fund any ambition you're hungry to achieve. like investing in everyone's dinner table. bank with sofi to earn a higher apy and an epic welcome bonus. sofi. get your money right. this thing, it's making me get an ice bath again. what do you mean? these straps are mind-blowing! th

our first guest ever from regeneron way back when the stock was at five dollars. it is down $913. they also have a plethora of winners. then amazing things. then i get to speak to karen lynch about house she is managing the cvs health transition from a drugstore to a healthcare provider. i think she has a lot of impressive things to stay. it used to be norman as american source bergen. it's one of the linchpins of the health care system. than we have one of the best medical device companies in the world. you might still be using their covid tests. you certainly might be using diabetes devices. then we will talk to the ceo of dickinson. then we also have ces the consumer tech show next week. i sure wish i could be both places. i expect them to remind people why stock rallied so hard and continue to do so. i'm looking for more information on initiatives which are not getting enough credit. then there is a fireside chat at the conference and i hope they talk about this new artificial intelligence on your pc. nobody paid attention to me when i spoke about that this week. homebuilders

. >>> regeneron in large cap biotech, more than meets the eye when it comes to this stock.ding at a new record high today. joe, you own this one in the joet etf. >> that report identifies all he need to know. a biopharma. this is a classic example how it does work. a name in the etf since january of 2022. the momentum is strong. >> citi is bullish on qualcomm. back over to you, jim. >> a lot of false dons picking up. hopefully what i'm about to say won't add to the series. that helps qualcomm but the automotive industry is restocking inventory. as the economy continues to expand, their internet of things business should be going well. eventually ai applications are going to take place on the phone and that will play strongly to qualcomm's strengths. >> shares up a third of a percent. >>> coming up our "chart of the day. " the committee is playing it up next on "halftime." it takes years of dedication to get to this milestone. the new york stock exchange is a symbol of what america is all about the potential of an american dream. it is day one. a lot of work has happened to

i have regeneron. i think i'm going to try to put some together right here right now.n't cnbc make some of the money. >> a new revenue silo for us? >> well, i mean, people say campbell doesn't make enough money. let's move into an ajensy. >> new cable under pressure we have to come up with new revenue sources. that could be one into sub fees and management fees. >> m&a investment club. >> it's big. >> you're coming back in the next hour. jim will return with his live interview with lilly's david ricks from the jpmorgan health care conference. lilly just a shade below all-time highs at 629 and change. dow down 264. 'rba ia me.t 's realty! hi! this listing sounds incredible. let's check it out. says here it gets plenty of light. and this must be the ocean view? of aruba? huh. this listing is misleading. well, when at&t says we give businesses get our best deal, on the iphone 15 pro made with titanium. we mean it. amazing. all my agents want it. says here...“inviting pool”. come on over! too inviting. only at&t gives businesses our best deals on any iphone. get iphone 15

. >> how about this regeneron call?verweight or outperform. 1076, jim, would be upside. >> this call is fantastic. and i say that because earlier this week, glen, who was on "mad money" at jpmorgan, people felt that his new -- let's just call it the more powerful drug, the one where you shoot it in your eye, macular degeneration, was disappointing. the numbers missed. what a buying opportunity. regeneron has a fantastic pipeline, and don't forget, they think that they have a holy grail obesity drug that would make it so you don't lose muscle. obviously, what happens with these obesity drugs is you lose everything across the board, and if you lose muscle and you're someone who's a senior citizen, you can't get the muscle back. i like this call. i think it's terrific. >> biggest laggard, jim, on the ndx, is tesla. we mentioned the production cuts in berlin. we talked to hertz yesterday about them cutting a third of their ev fleet. cutting prices in china. a piece today looking -- from morgan stanley, looking at the oems i

nd look towards the large cap and like the pharmaceuticals or regeneron and let's not forget about whatand also the medical device as well. and they will struggle. . >> the medical devices were hurt last year with fewer procedures or fear of it now. that's coming back. it's the vast sector as we all know. let's get to david george for his take on the regional bank results, david. i guess. so key threads that you would pull out of the numbers so far this quarter. the markets, they seem to be not really worrying about any adverse surprises, but also not that enthusiastic. >> yeah. good afternoon. i would say for my perspective, mike, the takeaway from this result is really stability. what i mean by that is revenues across the board have been pretty stable. expanses have been relatively well managed. and the quality for all the concerns out there about the consumer, they will continue to be in good shape. while the group has pulled back, keep that in mind. the banks are up. some profit taking is not surprising. if we will get a couple more days like this, it will be time to start getting m

regeneron is an inexpensive stock.ive because of the magnificent seven. >> how many interviews are you doing in two days? >> 17. >> in two days. >> last time my wife looked at my schedule, i count that you're doing 17 interviews. i said there's one more i just added. she said you're insane and went to bed. >> you're going to be a busy man. good for the viewer. see you tonight. jim will be at jpmorgan health care next week. when we come back, nec director lael brainard with white house reaction to the jobs numbers and a lot more as we have the dow hanging on to modest gains. don't go anywhere. - "best thing i've ever done." that's what freddie told me. - it was the best thing i've ever done, and- - really? - yes, without a doubt! - i don't have any anxiety about money anymore. - great people. different people, that's for sure, and all of them had different reasons for getting a reverse mortgage, but you know what, they all felt the same about two things: they all loved their home, and they all wanted to stay in that hom

we did a fantastic job with all of the medicines and -- if you look at regeneron, all of the things wetastic job. have never been given the credit for that. basically i allowed the governors to do their thing. henry mcmasters endorsed me. the governor of south carolina. almost every politician in south carolina endorsed me, which is tough for nikki. fauci became much more important for joe biden. he liked fauci. he was there for like 40 years. >> martha: he was out there every day in all of the news. >> if you listen to fauci, many of the things he recommended, he wanted to keep it open to china. i said no way. he admitted after that that i saved hundreds of thousands of lives. i closed it immediately to china. there was a room of 11 people. he was one of them. they all said no. now they give me credit for having closed it. it would have been worse. when ron goes out, i thought he was actually pretty gracious to be honest. i think the fact that he endorsed was a big factor. if you think about it, he wants low taxes. i gave the largest tax decrease or cut in the history of our country,

among the name's regeneron's drug for rhett tinnal diseases, astrazeneca cancer therapy and pfizer's rsv drug, it would be one of the first-ever rsv vaccine. our countydown closer is here to put a spin on the investment angle of it, could help the entire health care sector. $375 billion in assets under management. dana, right off the back the health care sector is very prod. it's got the hospitals, it's got insurers, it's got hospitals, it's got biotech. tell me which part of the health care area you like best? >> thanks for having me. i would say you first talked about pharma because i think that is a good place to lead in because we suddenly have this potential with these weight loss drugs for something i think is fairly revolutionary, right? certainly i think you will see increased interest there. more research and development, et cetera. it is kind of on the order of you know, baldness cure, right? if we can nail this down you can see a sort of asymetric payoff on it but i think at a high level when you look at health care i think the big news is the election here, which you were

regeneron then said please mister case, control your clients. what was it like to sit in that room? what sense did you get from judge or him go on, and how did other people react? >> i think that the judge knew that he had been played. obviously we saw that email exchange between judge engoron and the lawyers at the attorney generals office, and the lawyers representing trump. in that penultimate email he said to trump lawyer chris skies, take it or leave it. and yet, you saw a much more subdued judge engoron on thursday. he was almost exasperated. chris case stood up at the end of three attorneys presentations and he was at a time, and that's when he said your honor former president trump would like an opportunity to address the court. i think at that point, and gordon was exhausted. but i will also note alex, for you and our viewers, and go on had faced a bomb threat at this home that morning. not to say that former president trump was responsible for that, but i wonder how much a person can be attacked and threatens before they are just tired, and they give in. i think that's the

>> the only one that's making positive efforts is regeneron, which is a sort of large but not huge pharma company. but let's put this in perspective. $2 billion a year is spent on anti-aging, if you want to call it that, in the broad sense, and $200 billion around the world spent on pharma research. so, it's a very small trickle of money. but it's the most important thing of our time, because for the first time ever, it's possible to intervene in the fundamental biology of humans. >> when does big pharma catch on? >> as soon as there's a positive trial of some sort. and so, the trials are under way now, there's about 200 longevity companies, most of them in the united states, as you would expect. about 50, i would say, are legit, you know, companies that are potentially investable. all of them have the big challenge that you can't stay in business for 40 years to see if your drug works. so, you have to have a near-term commercial application, and so, for us, it's fibrosis with pi-1, with alzheimer's, it's obvious we're trying to stop the p progr progression. we have a good chance of being

so, the first and you'll see it on the screen is regeneron.hich reset the stock, stay long, be long. the next is virtex. these are sort of 100 billion plus, vrtx and you almost can't see that the chart changed. again, the definition of an orderly uptrend and so much better than the health care sector. now, the third is a different circumstance altogether. a real aggard. and you can see it here, medtronic. something that really took a hit. all the elements of a base or a bottom, and what i would characterize is a bearish to bullish guy. >> vertex is developing a nonopioid painkiller, which could be the holy grail in the opioid markets. i think everybody here likes health care to some extent? >> yes. well, some of the stocks that i've owned just had a terrible '23, after a great '22. names like america didn't do well. pfizer, of course, my pfizer -- >> yeah. >> really did terribly. i don't know if that's bottomed. bristol myers, one of them. there's a lot of value in the space. >> xlb, interesting way to play it. you look at the top three holdin

. >> regeneron is terrific. >> yes. and lily has been strong this year.ap. you may want to replace tesla with lily. >> that's a very good idea. it could be a -- >> get it close. get it close in market cap. one of the winners -- one of the people survived was, indeed -- david, one thing you need to know about lily, and i know about this with the work i did, we have yet to see their dementia drug, but their numbers are fabulous. >> that would be a wonderful deal. >> let's get the opening bell here in the real time exchange. on the big board. air taxi service, archer aviation. at the nasdaq, it is nbt bank corp. >> when you do the -- it rmemins me of that period, not 1999, but the period where anything could come public. >> 2021. it was the greatest time for spacs. and then they dropped price. but they eventually got to the public markets. obviously not trading anywhere near the $10 the spac once did. jobi is the other one. they're competing for this market. they once said it would 9 trillion. >> you will never forget that. >> no, i will never -- >> $9 trill